BriaCell Therapeutics Corp. BCTXF Archives - Page 3 of 6

ThursdayJan 31, 2019 11:20 am

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Leading the Way as Novel Therapies Fuel Growth of Breast Cancer Treatment Market

The market share of immunotherapy treatments for breast cancer and other malignancies is expected to increase exponentially by 2024 The incidence of breast cancer is set to grow by 50 percent in the next decade BriaCell Therapeutics Corp. has already established the effectiveness of its lead candidate, Bria-IMT, in clinical trials A personalized, off-the-shelf immunotherapy solution, Bria-OTS, is under development With the incidence of breast cancer expected to increase worldwide, the therapeutic market for this particular ailment is also set to grow at a CAGR of eight percent through 2023, according to industry reports (http://ibn.fm/HVYSA). Companies such as BriaCell Therapeutics Corp.…

ThursdayJan 24, 2019 2:33 pm

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Develops Unique Frozen Formulation of Bria-IMT

BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company focused on immuno-oncology, recently reported the impending clinical use of a novel frozen formulation of the company’s lead cancer drug candidate, Bria-IMT. The new, easy-to-use formulation can be transported more simply to distant locations. An article discussing the company reads, “The company’s frozen formulation allows for the storage of cryopreserved, ready-to-inject Bria-IMT for cold-chain overnight transport to clinical sites where it will be thawed prior to injection in patients. This unique formulation of Bria-IMT has also shown improved potency compared to the old formulation in vitro. Long term, this novel, frozen…

TuesdayJan 22, 2019 12:37 pm

BriaCell Therapeutics Corp.’s (OTCQB: BCTXF) (TSX.V: BCT) Development of Personalized Immunotherapy Focuses on Advanced Breast Cancer

Experienced management has been involved in over 10 drug approvals Developing Bria-OTS, the first off-the-shelf personalized immunotherapy targeting advanced breast cancer Impressive results in two proof-of-concept clinical trials revealed rapid response rate, repeated following re-treatment, and excellent safety profile for Bria-IMT, BriaCell’s lead clinical candidate Unmet medical needs of advanced breast cancer estimated between $1 billion and $5 billion, depending on treatment stage Developing Bria-OTS along with BriaDX, a companion diagnostic test, offering the ability to match and treat over 99 percent of the patient population with off-the-shelf personalized immunotherapy BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), an immuno-oncology focused…

WednesdayJan 16, 2019 12:05 pm

QualityStocksNewsBreaks – BriaCell Therapeutics Corp (OTC: BCTXF) (TSX.V: BCT) Advancing Development of Bria-IMT™ as Immunotherapy Solution for Advanced Breast Cancer Patients

BriaCell Therapeutics (OTC: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, is advancing the development of its lead product candidate Bria-IMT™, which has demonstrated positive results in three clinical studies to date. An article discussing the company reads, “Bria-IMT™ works by providing breast cancer antigens and a direct stimulation of the cancer fighting T-cells. This way, the therapy strengthens the body’s ability to fight cancer. Bria-IMT™ has achieved proof of concept in clinical trials, and its safety has also been assessed as excellent. Even in heavily pre-treated advanced breast cancer patients, Bria-IMT™ managed to elicit tumor…

FridayJan 11, 2019 12:31 pm

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT) Confident in the Future of Bria-IMT Following its Demonstrated Success in Clinical Trials

BriaCell Therapeutics (OTC: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, sees a promising future for its lead product candidate, Bria-IMT. An article discussing the company reads, “The company recently presented promising results for two of its clinical studies (monotherapy and combination study of Bria-IMT with pembrolizumab [KEYTRUDA®; manufactured by Merck & Co., Inc.]) for patients with advanced breast cancer during the 2018 San Antonio Breast Cancer Symposium in Texas (http://ibn.fm/0JGCl). … ‘I am very excited about our data continuing to show robust biological activity of Bria-IMT™ in advanced breast cancer,’ Dr. Bill Williams, BriaCell’s president…

MondayJan 07, 2019 1:22 pm

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Advances Novel Formulation of Drug Candidate in Battle against Advanced Breast Cancer

Development of frozen formulation of Bria-IMT completed for on-demand shipment to clinical sites Novel formulation is easily transportable to distant locations, easy to use, safe and has improved potency; it accommodates higher patient volumes at reduced per-dose costs Promising novel immunotherapy technology provides hope to patients with advanced breast cancer Breast cancer remains the leading cancer diagnosed in women and the second-most common cancer overall Immuno-oncology focused biotechnology company, BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) recently announced the imminent clinical use of a novel, frozen formulation of Bria-IMT, the company’s lead cancer drug candidate targeting the unmet medical needs…

WednesdayJan 02, 2019 12:40 pm

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT) Completes Novel Frozen Formulation of Bria-IMT; Announces Participation in Two Upcoming Conferences

BriaCell Therapeutics (OTC: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, today announced multiple updates including completion of its development of a novel frozen formulation of Bria-IMT, its upcoming attendance at the Biotech Showcase taking place Jan. 7-9, 2019 in San Francisco, and the acceptance of an abstract for presentation of advances in Bria-IMT and BriaDX programs at the 2019 Keystone Symposia scientific conference taking place Jan. 20-24, 2019, in Vancouver, British Columbia. According to the update, the new frozen Bria-IMT formulation will provide for on-demand shipment to clinical sites and accommodate higher volumes of patients…

FridayDec 28, 2018 12:02 pm

Kontrol Energy Corp. (CSE: KNR) (FSE: 1K8) Delivering Climate-Friendly Energy Solutions through Smart Administration of Utilities, HVAC

Multi-trillion-dollar energy efficiency industry provides hope for responding to growing global climate change trend Kontrol Energy Corp.’s SaaS model drove 35 percent revenue growth during past year as company delivered smart energy management solutions Company anticipates adding additional accretive acquisitions during the coming year and increasing recurring service revenues When Yale University reported recently that anxiety over the future of the planet’s climate system is rising significantly in the United States (http://ibn.fm/0eRLa), the Ivy League institution created a metric for the psychological consequences of sustained changes in regional weather patterns and the media reports about them. While climate change is driving…

FridayDec 28, 2018 11:41 am

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Advancing Its Clinical Program, Immunotherapy Seen as Future of Cancer Treatment

Multiple oncology and immunology organizations have identified immunotherapy as the future of cancer treatment BriaCell Therapeutics Corp. is making significant progress in the development of a safe and highly effective immunotherapy solution for advanced breast cancer patients The company is expected to announce new information about the efficacy of its lead product candidate in combination with KEYTRUDA® during the first quarter of 2019 Market forecasts suggest rapid anti-cancer immunotherapy market growth until 2023 For nearly 20 years, researchers have been working on ways to help the immune system better target cancer. New developments in the field are making that possible,…

ThursdayDec 27, 2018 2:38 pm

QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Advancing Clinical Development of its Novel Advanced Breast Cancer Treatment

BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), an immuno-oncology focused biotechnology company, is continuing its progression of Bria-IMT for the treatment of advanced breast cancer. An article discussing the company reads, “The Bria-IMT phase I/IIa monotherapy study involved 23 patients who were very heavily pre-treated (a median of four previous systemic therapy regiments per patient). The treatment with Bria-IMT was well-tolerated, with minor local irritation at the injection site being reported as the most common adverse effect. … More importantly, Bria-IMT contributed to tumor shrinkage in three of the patients. The top respondent previously received seven rounds of chemotherapy and had…

Site Search

Company Search

Tag: BriaCell Therapeutics Corp. BCTXF